Skip to navigation Skip to content

Clinical Trial: Antioxidant for fatigue in MS and other studies

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: Please see below
Number of Subjects: 182
Medication: Please see below
Location: Oregon|Washington
Institutions: Please see below Contact Information
Please see below

Funding:

Please see below

Description

Clinical Trial: Antioxidant for fatigue in MS
Type of MS: ALL MS TYPES, RRMS PPMS, SPMS
Treatment mode of action: ORAL
Number of Subjects: 60
Medication: Mitoquinone (MitoQ, an antioxidant)
Institution: Oregon Health Science University and Veterans Affairs Portland Medical Center
Address:  3181 S.W. Sam Jackson Park Road Portland, OR
Contact Name: Allison Fryman, MPH - Research Coordinator
Phone: 503-220-8262 x54594
Email: fryman@ohsu.edu
Funding: VA Merit Grant
Brief Description: The purpose of this study is to determine whether MS patients who receive oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
 
Clinical Trial: Physical therapy to prevent or reduce falls
Type of MS: any
Treatment mode of action: To prevent or reduce falls
Number of Subjects: 78
Medication: none
Institution: Oregon Health & Science University
Address: 3181 SW Sam Jackson Park Rd, Portland, OR 97239
Contact Name: Andrea Hildebrand
Phone: 503-220-8262 x52016
Email: hildeand@ohsu.edu
Funding: National MS Society
Brief Description: Dr. Michelle Cameron, a neurologist at OHSU and at the VA Portland Health Care System, is recruiting for the ADSTEP research study, which explores whether a training program on improving walking aid use can prevent and reduce falls in people with MS who use a walking aid.
If you would like to participate you must:
- Be over the age of 18
- Have multiple sclerosis
- Have fallen at least once in the past year
- Use an assistive device such as a walker, crutch, or cane
- Be able to walk at least 25 feet with or without your walking aid
- Have had no multiple sclerosis relapses within the past 30 days
- Have access to a device compatible with video conferencing and reliable internet
Connection
 
Participants will be randomly placed in one of two groups. Half of the participants will receive a
telehealth training program of six weekly sessions with a physical therapist. The other half will
receive educational materials on walking aids and fall prevention and will be invited to take the
training program or receive device adjustment after the study is completed. In addition to class
time, participants will complete three remote assessment visits over an 8-month period. You will also be asked to keep a daily record of your falls during this time.
 
Research Study: Vascular Comorbidities ad the Retina
Type of MS: Relapsing-remitting MS
Treatment mode of action: N/A – observational study
Number of Subjects: 44
Medication: N/A
Institution: Portland VA Medical Center and OHSU
Address: 3710 SW US Veterans Hospital Rd, Portland, OR 97239
Contact Name: Emma Chase
Phone: 503-494-3549
Email: chaseem@ohsu.edu
Funding: Portland VA Research Foundation
Brief Description: (Please note, this is a research study, and not a clinical trial testing an intervention.) The purpose of this research study is to understand more about how vascular comorbidities, such as high blood pressure and high cholesterol, impact the retinal vasculature in people with relapsing remitting MS aged 30 – 70. In addition, we are aiming to better understand how changes of the retinal vasculature and neuronal structural integrity relate over time. The study involves 5 visits to the Portland VA Medical Center and OHSU over 2 years. During these visits you will have vision tests performed, complete questionnaires, have a blood draw, and a neurological exam. During your first and last visits, you will have a 45-minute MRI scan.
 
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.